Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Operating Expenses (2016 - 2025)

IGC Pharma has reported Operating Expenses over the past 16 years, most recently at $3.0 million for Q3 2025.

  • Quarterly Operating Expenses rose 53.12% to $3.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Sep 2025, down 14.09% year-over-year, with the annual reading at $8.1 million for FY2025, 23.61% down from the prior year.
  • Operating Expenses was $3.0 million for Q3 2025 at IGC Pharma, up from $2.1 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $6.6 million in Q1 2022 and troughed at $1.6 million in Q1 2025.
  • The 5-year median for Operating Expenses is $2.6 million (2024), against an average of $2.9 million.
  • Year-over-year, Operating Expenses skyrocketed 157.7% in 2021 and then crashed 42.82% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $2.4 million in 2021, then dropped by 2.74% to $2.4 million in 2022, then surged by 31.55% to $3.1 million in 2023, then crashed by 36.7% to $2.0 million in 2024, then skyrocketed by 51.26% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Operating Expenses are $3.0 million (Q3 2025), $2.1 million (Q2 2025), and $1.6 million (Q1 2025).